A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy [Eine randomisierte; doppelblinde placebokontrollierte Studie der Phase 2/3 zur Beurteilung der Sicherheit und Wirksamkeit von Davunetide zur Behandlung von progressiver supranukleärer Blickparese]

Trial Profile

A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy [Eine randomisierte; doppelblinde placebokontrollierte Studie der Phase 2/3 zur Beurteilung der Sicherheit und Wirksamkeit von Davunetide zur Behandlung von progressiver supranukleärer Blickparese]

Completed
Phase of Trial: Phase II/III

Latest Information Update: 24 Apr 2017

At a glance

  • Drugs Davunetide (Primary)
  • Indications Progressive supranuclear palsy
  • Focus Adverse reactions; Biomarker; Pharmacogenomic; Registrational; Therapeutic Use
  • Sponsors Allon Therapeutics
  • Most Recent Events

    • 24 Apr 2017 Results of a post-hoc analysis from NCT01110720 and NCT01049399 studies, published in the Movement Disorders.
    • 20 Jun 2013 Results presented at the 17th International Congress of Parkinson's Disease and Movement Disorders.
    • 18 Dec 2012 Primary endpoints 'Assessment-scale-scores' (Progressive Supranuclear Palsy Rating Scale) and 'Schwab and England Disability Scale' have not been met according to an Allon Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top